Читать книгу Recent Advances in the Pathogenesis and Treatment of Kidney Diseases - Группа авторов - Страница 27

We demonstrated that rituximab treatment was effective and safe in adult patients with steroid-dependent MCNS and dose reduction or discontinuation of the steroid. In addition, rituximab leads to the amelioration of adverse effects of the steroid. Only infusion reactions, such as rash and chills, occurred after single-dose rituximab infusion, and these reactions could be managed by premedication or infusion rate adjustments. Consequently, careful clinical monitoring is mandatory for these patients. The measurement of the peripheral CD19 cell count seems to be a crude monitoring tool, but it is not a reliable means of deciding whether to proceed with rituximab therapy. Controlled randomized trials that include adult patients with steroid-dependent MCNS are required to prove the efficacy and safety of rituximab and to evaluate the cost-effectiveness of rituximab treatment.